Are another 5 years of adjuvant aromatase inhibitor therapy needed?
Qin-Guo Mo*, De-Quan Li*, Jian-Hong Zhong, Chang-Yuan Wei
Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People’s Republic of China
*These authors contributed equally to this work
In the recent issue of Breast Cancer: Targets and Therapy, some questions about adjuvant systemic therapy1 and bone loss and skeletal-related events in postmenopausal women with hormone receptor-positive breast cancer2 were discussed by two reviews.
View original paper by Leone and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]